Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
about
DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerTargeting the Checkpoint to Kill Cancer CellsDecarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction.ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.Targeting lung cancer through inhibition of checkpoint kinases.A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma.BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder.Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer.ATR Kinase Inhibition Protects Non-cycling Cells from the Lethal Effects of DNA Damage and Transcription Stress.ATM protein is deficient in over 40% of lung adenocarcinomas.Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cellsTargeting DNA Repair in Cancer: Beyond PARP Inhibitors.Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitorsDrugging ATR: progress in the development of specific inhibitors for the treatment of cancer.Molecular Pathways: Targeting ATR in Cancer TherapyPersonalised Medicine: Genome Maintenance Lessons Learned from Studies in Yeast as a Model Organism.Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint.Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.Targeting the ATR-CHK1 Axis in Cancer TherapyThe cell cycle checkpoint inhibitors in the treatment of leukemias.The Future of Radiobiology.ATR/CHK1 inhibitors and cancer therapy.Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.LC-MS/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma.HUS1 regulates in vivo responses to genotoxic chemotherapies.Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.Approaches for Identifying Novel Targets in Precision Medicine: Lessons from DNA Repair.Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.DNA repair pathways and cisplatin resistance: an intimate relationshipThe Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation
P2860
Q26776513-C432E85B-471C-49E2-B192-20AF059534E2Q26795781-1092298E-5CD0-40CB-9892-E882A3D9CA07Q34456932-DF54BB72-B347-41AB-9558-8D5EBF30DD95Q34614944-72D8C1E9-CAAC-47C2-8EEE-1EE9742189D7Q35128547-8F664FEF-D122-426F-B28E-7B619F2FC9BEQ35627868-86BDEDB7-8DB2-4649-97BF-DB5669EB939CQ35799909-5C3B4B11-8B81-4B36-80B0-89DE19F795A8Q36188973-FBFE285C-D03A-46CF-AF3D-40C272BF3D13Q36544857-E6311F72-9A34-495A-9693-2C4CB9FC01EFQ36688959-E2CD452F-52CA-4D76-B71C-608AC6671CFBQ36739002-C7229E91-32D9-421E-AEF5-8275F66126D5Q36855596-5C4813C1-D739-4B13-B1BC-F292D9B87EE5Q36884873-87A3CD57-558B-4629-A9BD-D8D019B938D1Q37628924-D5D7D91B-FC7B-44DA-8190-70F5E0F80E4AQ37630747-F4B45054-E1D3-4D19-A597-AE16B472F298Q37634102-42C4C012-68F6-4DB8-AD91-87587A2BF962Q37635766-171701FD-FE29-420F-8429-15F6121B8FC1Q38261022-F3BEE76C-5EFF-4BAD-A3C2-2D028306FFA3Q38523589-841E5C5B-B5B7-4AED-8100-01C00C8F2667Q38585436-CE808636-6A6F-48E8-B06F-249AB4E14D1BQ38608688-41D9ABFE-0967-4F54-8D5F-B0F6CBF1425AQ38698806-E5D7F8AB-8C31-4019-9334-1205EE24D97BQ38702556-F3211ABD-FBDE-41B9-A21E-2B63FDCB3052Q38817102-220A2B9E-B17A-48DA-A081-348935827695Q38868502-3CCF0533-4CA7-49BD-BA7A-493F3DEEBE4AQ46136392-32E1C7C7-1CE3-486E-AE51-C91F67DE6D96Q47622968-F5986334-59FD-425C-9A57-2A006474BFD1Q47786231-BAB4B2E8-1B91-41B3-9534-B87F2D553E10Q47829412-CF48B7A0-FD05-4BCA-8482-33DF5C5D4AAEQ48195510-A680FDB5-11A0-4243-8BB1-7F23EF560EB7Q49679908-E3B1DA85-3F0A-44E4-84C9-3836376C6331Q50958792-89FB1B62-84BC-4A40-ADAF-378A9707F9C2Q51800946-67EE2F13-DEBC-44CD-8C19-F56F72670528Q52428057-EC988FBB-1C0B-40B8-85D9-4F911FAEF99BQ55710290-2E6B8364-0D1D-4456-B4AD-4BF019A5A38BQ58699219-C509BAA7-5105-41B5-B6B5-EB577E9256E6Q58734520-0BA1C0C6-A326-4561-A39B-AB7221C010E4
P2860
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Potentiation of tumor response ...... selective ATR inhibitor VX-970
@ast
Potentiation of tumor response ...... selective ATR inhibitor VX-970
@en
Potentiation of tumor response ...... selective ATR inhibitor VX-970
@nl
type
label
Potentiation of tumor response ...... selective ATR inhibitor VX-970
@ast
Potentiation of tumor response ...... selective ATR inhibitor VX-970
@en
Potentiation of tumor response ...... selective ATR inhibitor VX-970
@nl
prefLabel
Potentiation of tumor response ...... selective ATR inhibitor VX-970
@ast
Potentiation of tumor response ...... selective ATR inhibitor VX-970
@en
Potentiation of tumor response ...... selective ATR inhibitor VX-970
@nl
P2093
P2860
P356
P1433
P1476
Potentiation of tumor response ...... selective ATR inhibitor VX-970
@en
P2093
Amy B Hall
Brenda Eustace
Brian Hare
Brinley Furey
Cheryl E Murphy
Crystal Tolman
Darin Takemoto
Dave Newsome
Diane M Boucher
Jean-Damien Charrier
P2860
P304
P356
10.18632/ONCOTARGET.2158
P407
P577
2014-07-01T00:00:00Z